Wide Ranks

MESO

Mesoblast Limited

11.58

Top Statistics
Market Cap 1 B Forward PE -21.05 Revenue Growth -41.20 %
Current Ratio 1.18 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -236.67 Enterprise / Revenue 2248.65 Price To Sales Trailing12 Months 224.02
Profitability
Profit Margins 0.00 % Operating Margins -1248.53 %
Balance Sheet
Total Cash 62 M Total Cash Per Share 0.0550 Total Debt 118 M
Total Debt To Equity 24.76 Current Ratio 1.18 Book Value Per Share 0.4210
All Measures
Short Ratio 873.00 % Message Board Id finmb_20356678 Fax 61 3 9639 6030
Shares Short Prior Month 1 M Return On Equity -0.1791 City Melbourne
Uuid cb226b99-e7ae-3bd6-b05f-2314b416f7a7 Previous Close 11.05 First Trade Date Epoch Utc 1 B
Book Value 0.4210 Beta 2.34 Total Debt 118 M
Volume 116412 Price To Book 27.51 Last Split Date 1 B
Fifty Two Week Low 1.61 Total Cash Per Share 0.0550 Total Revenue 5 M
Shares Short Previous Month Date 1 B Target Median Price 14.50 Max Age 86400
Sand P52 Week Change 0.3133 Operating Margins -1248.53 % Target Mean Price 14.50
Net Income To Common -87956000 Short Percent Of Float 0.0192 Implied Shares Outstanding 170 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 245060
Average Volume10days 245060 Total Cash 62 M Next Fiscal Year End 1 B
Revenue Per Share 0.0600 Held Percent Insiders 0.0007 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 11.05
Target Low Price 11.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 9.27
Open 11.27 Free Cashflow -27316582 State VIC
Dividend Yield 0.00 % Return On Assets -0.0541 Time Zone Short Name EST
Trailing Eps -1.22 Day Low 11.26 Address1 55 Collins Street
Shares Outstanding 114 M Price Hint 2 Target High Price 18.00
Website https://www.mesoblast.com 52 Week Change 3.26 Average Volume 190035
Forward Eps -0.5500 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 113.90 % Last Split Factor 1:2 Regular Market Day High 11.70
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 24.76
Fifty Two Week High 12.18 Day High 11.70 Shares Short 1 M
Regular Market Open 11.27 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 2248.65 Revenue Growth -41.20 % Shares Percent Shares Out 0.0147
Operating Cashflow -48458000 Currency USD Time Zone Full Name America/New_York
Market Cap 1 B Is_nasdaq_100 False Zip 3000
Quote Type EQUITY Industry Biotechnology Long Name Mesoblast Limited
Regular Market Day Low 11.26 Held Percent Institutions 0.0144 Current Price 11.58
Address2 Level 38 Enterprise To Ebitda -236.67 Financial Currency USD
Current Ratio 1.18 Industry Disp Biotechnology Number Of Analyst Opinions 2
Country Australia Float Shares 848 M Two Hundred Day Average 6.72
Enterprise Value 13 B Price To Sales Trailing12 Months 224.02 Forward PE -21.05
Regular Market Volume 116412 Ebitda -56077000 Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.

Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.

The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease.

It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy.

It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure and MPC-25-IC for the treatment or prevention of acute myocardial infarction; JCR Pharmaceuticals Co.

Ltd.

to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain.

The company was incorporated in 2004 and is headquartered in Melbourne, Australia.